25-MAR-2025 6:10

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY ADMIN CCADMIN ACCR.
GOAL		 R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol PEOLC   491 1 Y 0 Screening 361 32 32 27 8 1
              361 32 32 27 8 1
 
        2 Y 1 Carvedilol 74 0 0 0 0 0
            2 No prophylaxis 81 0 0 0 0 0
            3 Observation 177 22 22 22 9 1
              332 22 22 22 9 1
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 739 1 Y 0 Screening 581 92 50 25 10 2
              581 92 50 25 10 2
 
        2 Y 1 Control (Usual Care) 197 34 19 10 2 0
            2 Intervention (STMDDM) 199 35 21 10 5 1
              396 69 40 20 7 1
 
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum GU SXQOL 1273 1 Y 0 Induction SST 893 112 45 24 11 3
              893 112 45 24 11 3
 
        2 Y 1 Standard Systemic Therapy Only 322 47 18 7 2 0
            2 SST + Surgery/RT 320 44 17 7 0 0
              642 91 35 14 2 0
 
S1803-MM, Maintenance, Len vs Len/Dara MMYEL SXQOL 1100 2 Y 1 Lenalidomide 669 120 56 21 1 1
            2 Lenalidomide + Daratumumab 658 116 53 18 3 0
              1327 236 109 39 4 1
 
        3 Y 3 Continue Lenalidomide 36 10 6 4 2 0
            4 Stop Lenalidomide 38 11 8 4 2 0
            5 Continue Lenalidomide + Dara 88 29 16 11 6 0
            6 Stop Lenalidomide + Dara 90 31 19 11 6 1
              252 81 49 30 16 1
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 668 1 Y 1 PCI + MRI brain surveillance 136 31 17 10 4 1
            2 MRI brain surveillance 133 29 16 8 2 0
              269 60 33 18 6 1
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 422 1 Y 1 CC-486 + R-miniCHOP 69 23 11 5 3 0
            2 R-miniCHOP 67 21 10 7 3 1
              136 44 21 12 6 1
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 247 1 Y 1 Delayed V-O 49 17 9 7 1 0
            2 Early V-O 89 26 14 8 3 0
              138 43 23 15 4 0
 
S2013-I-CHECKIT: ICI toxicity risk prediction study SXQOL   3609 1 Y 1 Observation Arm 2153 221 69 59 25 6
              2153 221 69 59 25 6
 
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes SXQOL   777 1 Y 1 Cryocompression 110 75 37 19 8 2
            2 Continuous Compression 107 71 35 20 8 0
            3 Low Cyclic Compression 109 71 38 18 7 1
              326 217 110 57 23 3
 
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva BREAST SXQOL 960 1 Y 1 Tissue for MammaPrint testing 421 389 238 127 59 10
              421 389 238 127 59 10
 
        2 Y 2 SOC Chemotherapy 69 66 44 23 10 3
            3 SOC Chemotherapy + Durvalumab 66 63 41 21 7 0
              135 129 85 44 17 3
 
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa LYMPH SXQOL 227 1 Y 1 Tazemetostat (Arm 1) Dose Level 1 7 6 0 0 0 0
            4 Zanubrutinib (Arm 3) Dose Level 1 10 4 0 0 0 0
            5 Zanubrutinib (Arm 3) Dose Level 2 10 10 4 0 0 0
              27 20 4 0 0 0
 
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D MMYEL SXQOL 510 1 Y 1 VRD-R 23 18 10 4 1 0
            2 DRD-R 24 18 9 4 2 0
            3 DRD-DR 22 17 9 4 2 0
              69 53 28 12 5 0
 
S2212-Breast, TNBC, Neoadj Chemo + Pembro BREAST SXQOL 2400 1 Y 1 Carbo + Paclitaxel + Pembro -> AC + Pembro 274 234 129 65 23 5
            2 Carbo + Docetaxel + Pembro 276 233 134 63 25 4
              550 467 263 128 48 9
 
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 338 1 Y 0 Induction 11 11 8 6 2 0
              11 11 8 6 2 0
 
        2 Y 1 Dara-VCD 2 2 2 1 1 0
            2 Melphalan + ASCT 2 2 2 1 0 0
              4 4 4 2 1 0
 
        3 Y 3 Dara 1 1 1 1 1 0
              1 1 1 1 1 0
 
S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo GI SXQOL 224 1 Y 1 Nivolumab + Paclitaxel + Ramucirumab 10 10 10 4 3 0
            2 Paclitaxel + Ramucirumab 9 9 5 2 0 0
              19 19 15 6 3 0
 
S2408-Panc, Lanreotide PEOLC   274 1 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance LUNG SXQOL 306 1 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL   1 E   54 13 7 4 1 1
              54 13 7 4 1 1
 
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab BREAST SXQOL   1 E   20 15 9 6 3 0
              20 15 9 6 3 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL   0 E   40 5 4 3 1 0
              40 5 4 3 1 0
 
        1 E   33 4 3 2 1 1
              33 4 3 2 1 1
 
A032103-Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL   0 E   22 21 20 14 7 3
              22 21 20 14 7 3
 
        1 E   10 10 8 7 3 1
              10 10 8 7 3 1
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub LYMPH SXQOL   1 E   17 14 8 3 1 1
              17 14 8 3 1 1
 
        2 E   6 5 3 3 0 0
              6 5 3 3 0 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL   1 E   88 15 4 1 1 1
              88 15 4 1 1 1
 
A211901-Cancer survivors who smoke, txt cessation SXQOL     1 E   13 9 1 0 0 0
              13 9 1 0 0 0
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD     1 T   54 0 0 0 0 0
              54 0 0 0 0 0
 
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy LYMPH SXQOL   1 E   47 33 22 15 9 4
              47 33 22 15 9 4
 
        2 E   31 19 14 6 2 0
              31 19 14 6 2 0
 
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx OTHER SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
        2 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno LUNG SXQOL   1 E   2 2 1 1 0 0
              2 2 1 1 0 0
 
        2 E   2 2 1 1 0 0
              2 2 1 1 0 0
 
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) MMYEL SXQOL   0 E   52 6 3 2 1 1
              52 6 3 2 1 1
 
        1 E   37 3 1 0 0 0
              37 3 1 0 0 0
 
        2 E   29 14 5 2 0 0
              29 14 5 2 0 0
 
EAQ211-Lymph, Survivors, Health Disp. AYA SURV     1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
EAQ222CD-CostCOM, Cancer Patients, OOP Cost Com CCD     0 E   15 15 14 9 2 1
              15 15 14 9 2 1
 
        1 E   13 13 12 8 4 1
              13 13 12 8 4 1
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL   1 E   52 26 13 9 5 0
              52 26 13 9 5 0
 
        2 E   49 24 11 7 4 1
              49 24 11 7 4 1
 
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction SXQOL OTHER   1 E   13 6 2 0 0 0
              13 6 2 0 0 0
 
NRGCC011-Breast, Survivors, Cog Training SXQOL     0 E   46 46 22 10 4 1
              46 46 22 10 4 1
 
        1 E   30 30 19 4 2 1
              30 30 19 4 2 1
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL   1 E   14 2 0 0 0 0
              14 2 0 0 0 0
 
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx GU SXQOL   1 E   15 6 4 4 2 1
              15 6 4 4 2 1
 
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo LUNG SXQOL   1 E   2 1 0 0 0 0
              2 1 0 0 0 0
 
A012301-Breast, Early Stg, Tamoxifen BREAST SXQOL   1 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
A021804-Adren, Advanced Stg, Temo w/wo Ola GU     1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
A031801-GU, mRCC, Cabozantinib ± Radium-223 GU SXQOL   1 E   15 1 0 0 0 0
              15 1 0 0 0 0
 
A082002-Lung, Adv, Systemic Tx +/- SBRT LUNG SXQOL   1 E   4 0 0 0 0 0
              4 0 0 0 0 0
 
A191901-Brst, Text/Motivational Intervention ET Adher CCD     1 E   42 3 2 1 1 0
              42 3 2 1 1 0
 
A212102-Blind Ref Set for Multicancer Early Detection PREV     1 E   197 109 59 25 18 4
              197 109 59 25 18 4
 
A222004-Mult, Olanza vs Megestrol for Anorexia SXQOL     1 E   7 4 1 0 0 0
              7 4 1 0 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD     1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis SXQOL     1 E   4 4 2 2 1 0
              4 4 2 2 1 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL   1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL   1 T   5 1 1 0 0 0
              5 1 1 0 0 0
 
CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad GI SXQOL   1 E   3 3 0 0 0 0
              3 3 0 0 0 0
 
CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever GI SXQOL   1 E   4 4 2 0 0 0
              4 4 2 0 0 0
 
CE7-Brain, 5+ Metastases, Radiosurg/Radiotherapy OTHER SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
        2 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
EA2185-Panc, Impact of Panc Cyst Surveillance PREV SXQOL   1 E   19 0 0 0 0 0
              19 0 0 0 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL   1 E   15 3 2 2 1 0
              15 3 2 2 1 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
EA8184-Pros, Dbl Blind GTC vs Placebo PREV SXQOL   0 E   27 15 7 3 1 0
              27 15 7 3 1 0
 
        1 E   12 8 5 2 2 1
              12 8 5 2 2 1
 
EA8191-Pros, Local vs Systemic Thrpy GU SXQOL   0 E   65 37 17 5 0 0
              65 37 17 5 0 0
 
        1 E   65 37 17 5 0 0
              65 37 17 5 0 0
 
EA8212-Blad, NMIBC, BRIDGE GU SXQOL   1 E   214 122 64 33 11 0
              214 122 64 33 11 0
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL   0 E   75 15 4 0 0 0
              75 15 4 0 0 0
 
        1 E   37 11 4 0 0 0
              37 11 4 0 0 0
 
EAQ202-Improving AYA PROs in EA Trials SXQOL     1 E   43 0 0 0 0 0
              43 0 0 0 0 0
 
EAQ221CD-Breast, Metastatic, Imp. Adherence CCD     0 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL   1 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
        2 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
NRGBN011-Brain, Lomustine + Temo vs Temo OTHER SXQOL   1 E   37 22 15 7 4 0
              37 22 15 7 4 0
 
        2 E   11 7 5 2 0 0
              11 7 5 2 0 0
 
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg OTHER SXQOL   1 E   4 3 0 0 0 0
              4 3 0 0 0 0
 
NRGBR007-Breast, Stg I, De-Escalation of Breast RT BREAST SXQOL   1 E   21 13 9 4 2 0
              21 13 9 4 2 0
 
        2 E   19 11 7 3 2 0
              19 11 7 3 2 0
 
NRGBR008-Breast, LowRisk HER2+, Radiotherapy BREAST SXQOL   1 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
NRGBR009-Breast, EarlyStg, Adjuvant Chemo BREAST SXQOL   1 E   11 8 5 3 2 0
              11 8 5 3 2 0
 
        2 E   11 8 5 3 2 0
              11 8 5 3 2 0
 
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs PREV     1 E   51 48 31 16 9 3
              51 48 31 16 9 3
 
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO PREV SXQOL   1 E   11 2 0 0 0 0
              11 2 0 0 0 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL   1 Y   15 0 0 0 0 0
              15 0 0 0 0 0
 
NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT GI SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
        2 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
NRGGU009-Pros, PREDICT-RT GU SXQOL   1 E   91 47 13 3 0 0
              91 47 13 3 0 0
 
        2 E   84 42 10 4 0 0
              84 42 10 4 0 0
 
NRGGU010-Pros, Parallel De-Intens & Intens Trials GU SXQOL   1 E   67 35 17 1 0 0
              67 35 17 1 0 0
 
        2 E   62 32 17 1 0 0
              62 32 17 1 0 0
 
NRGGU013-Prostate, High-Risk, Five Fraction Radiation GU SXQOL   1 E   5 5 1 0 0 0
              5 5 1 0 0 0
 
NRGGY026-Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE OTHER SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
NRGHN006-HN, Erly Stg, Biopsy vs Dissection OTHER SXQOL   1 E   3 2 0 0 0 0
              3 2 0 0 0 0
 
        2 E   3 1 0 0 0 0
              3 1 0 0 0 0
 
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN OTHER SXQOL   1 E   18 5 1 1 1 0
              18 5 1 1 1 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL   1 E   7 1 1 0 0 0
              7 1 1 0 0 0
 
        2 E   6 1 1 0 0 0
              6 1 1 0 0 0
 

25-MAR-2025 6:10

Cancer Coltrol Open Studies with No Registrations

Study Admin CCAdmin Registration/Phase Open Date
S2408 Panc, Lanreotide PEOLC   1 Randomization 14-Feb-25
S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance LUNG SXQOL 1 Randomization 14-Mar-25
A032103 Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL 2 Re-Registration 09-Jan-24
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis SXQOL   2 Callback 14-Aug-23
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL 2 Late Randomization Callback 08-May-17
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 2 Randomization2 08-Sep-17